Literature DB >> 30023087

Efficacy and immune activation of ipilimumab in early-stage lung cancer patients.

Shingo Noguchi1, Kazuhiro Yatera1.   

Abstract

Entities:  

Year:  2018        PMID： 30023087      PMCID： PMC6036029          DOI： 10.21037/jtd.2018.05.108

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  15 in total

1.  Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab.

Authors:  John S Yi; Neal Ready; Patrick Healy; Chelsae Dumbauld; Robyn Osborne; Mark Berry; Debra Shoemaker; Jeffrey Clarke; Jeffrey Crawford; Betty Tong; David Harpole; Thomas A D'Amico; Frances McSherry; Frank Dunphy; Shannon J McCall; Jared D Christensen; Xiaofei Wang; Kent J Weinhold
Journal:  Clin Cancer Res       Date:  2017-09-26       Impact factor: 12.531

2.  Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.

Authors:  Spencer C Wei; Jacob H Levine; Alexandria P Cogdill; Yang Zhao; Nana-Ama A S Anang; Miles C Andrews; Padmanee Sharma; Jing Wang; Jennifer A Wargo; Dana Pe'er; James P Allison
Journal:  Cell       Date:  2017-08-10       Impact factor: 41.582

3.  Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes.

Authors:  Shigehisa Kitano; Michael A Postow; Carly G K Ziegler; Deborah Kuk; Katherine S Panageas; Czrina Cortez; Teresa Rasalan; Mathew Adamow; Jianda Yuan; Philip Wong; Gregoire Altan-Bonnet; Jedd D Wolchok; Alexander M Lesokhin
Journal:  Cancer Immunol Res       Date:  2014-05-20       Impact factor: 11.151

4.  Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients.

Authors:  Shigehisa Kitano; Takemasa Tsuji; Caillian Liu; Daniel Hirschhorn-Cymerman; Chrisann Kyi; Zhenyu Mu; James P Allison; Sacha Gnjatic; Jianda D Yuan; Jedd D Wolchok
Journal:  Cancer Immunol Res       Date:  2013-10       Impact factor: 11.151

5.  Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.

Authors:  J Shimizu; S Yamazaki; S Sakaguchi
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

6.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

7.  Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

Authors:  Thomas J Lynch; Igor Bondarenko; Alexander Luft; Piotr Serwatowski; Fabrice Barlesi; Raju Chacko; Martin Sebastian; Joel Neal; Haolan Lu; Jean-Marie Cuillerot; Martin Reck
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

8.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors:  Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

9.  Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.

Authors:  Anna Maria Di Giacomo; Luana Calabrò; Riccardo Danielli; Ester Fonsatti; Erica Bertocci; Isabella Pesce; Carolina Fazio; Ornella Cutaia; Diana Giannarelli; Clelia Miracco; Maurizio Biagioli; Maresa Altomonte; Michele Maio
Journal:  Cancer Immunol Immunother       Date:  2013-04-17       Impact factor: 6.968

10.  Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.

Authors:  M Reck; I Bondarenko; A Luft; P Serwatowski; F Barlesi; R Chacko; M Sebastian; H Lu; J-M Cuillerot; T J Lynch
Journal:  Ann Oncol       Date:  2012-08-02       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.